|
시장보고서
상품코드
1463764
세계의 레드 바이오테크놀러지 시장 : 시장 규모, 점유율 분석(용도별, 제품별, 최종사용자별) - 산업 수요 예측(-2030년)Red Biotechnology Market Size and Share Report by Application, Product, End User - Global Industry Demand Forecast to 2030 |
||||||
주요 하이라이트
세계의 레드 바이오테크놀러지 시장은 2023년에 5,767억 달러, 2030년에는 1조 1,723억 달러 규모에 달하며, 10.5% 이상의 CAGR로 성장할 전망입니다.
임상시험·Drug Discovery·보인자 스크리닝·진단에서 요구의 증가와 유전성 질환의 이환율 상승이 업계의 확대를 지원하고 있습니다.
주요 인사이트
바이오의약품 생산은 2023년에 25.0%의 점유율로 업계를 선도하며, 이 10년간은 계속 한층 더 선도할 전망입니다.
2023년에는 인간 백신이 30.0%의 점유율로 업계를 선도하며, 이 10년간은 이 동향이 계속될 전망입니다.
2023년에는 북미가 약 55%의 점유율로 업계를 선도하고 있으며, 향후 수년간 한층 더 견고한 성장을 보일 전망입니다.
아시아태평양은 가장 빠른 페이스로 진보하고 있습니다. 이것은 이 지역의 해외 및 국내 바이오테크놀러지 기업으로부터의 자금조달이 증가하고 있고, 감염증 및 만성질환 환자가 방대하게 존재하기 때문입니다.
세계의 레드 바이오테크놀러지 시장을 분석했으며, 시장의 기본 구조·최신 상황 및 주요 촉진·억제요인, 세계 전체 및 지역별·주요 국가의 시장 규모 동향 전망(금액 기반, 2017-2030년), 용도별·제품별·최종사용자별 상세 동향, 현재의 시장 경쟁 상황, 주요 기업의 개요 등을 조사하여 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 업계 전망
- 시장 역학
- 동향
- 촉진요인
- 억제요인/과제
- 촉진요인/억제요인의 영향 분석
- 신종 코로나바이러스 감염증(COVID-19)의 영향
- Porter's Five Forces 분석
제6장 세계 시장
- 개요
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 제품별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
- 시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 제품별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
- 시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아태평양 시장
제10장 라틴아메리카 시장
제11장 중동 및 아프리카 시장
제12장 미국 시장
- 개요
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 제품별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카공화국 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 참여 기업과 제공 제품/서비스 리스트
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근 전략 개발 상황
제30장 기업 개요
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Novartis AG
제31장 부록
KSA 24.04.30Key Highlights
The red biotechnology market generated a value of USD 576.7 billion in 2023, and it will increase to USD 1,172.3 billion, advancing at more than 10.5% compound annual growth rate, by 2030.
The increasing need for it in clinical trials, drug discovery, carrier screening, and diagnostics, along with the rising incidence of genetic disorders aid the industry expansion.
Effective product development as well as genetic engineering relating to new drugs for treating life-threatening ailments are the key benefits of red biotechnology.
The increasing technological advancement rate in gene sequencing platforms, rising investment from private bodies and government for large-scale biotechnology plans, and substantial acceptance of red biotechnology across different applications like veterinary sciences, tissue engineering, and poultry farming, resulted in the industry expansion.
The increasing incidence of cancer and the surging use of this technology in cancer research & diagnostics are major drivers for this industry.
These technologies are employed for producing combination vaccines, including those that target Hepatitis A, Hepatitis B, polio, and diphtheria at once.
The rising count of R&D initiatives by major players, particularly in the area of stem cells, is a major trend in this industry.
Likewise, the pandemic of COVID-19 and a rising count of research studies discovering the use of this method for developing medicines, vaccines, and diagnostic tools assist industry expansion.
Key Insights
Biopharmaceutical production led the industry in 2023, with a 25.0% share, and it will further remain leading throughout this decade.
The increasing need for proteins, antibodies, antisense oligonucleotides, RNA, and DNA for diagnostic and therapeutic purposes is boosting the biopharmaceutical production category growth.
Gene therapy is likely to propel at the fastest compound annual growth rate in the years to come. The increasing incidence of genetic disorders as well as cancers is driving this category.
The human vaccines category led the industry in 2023, with a share of 30.0%, and it will continue this trend throughout this decade.
The human vaccines category growth is because of the increasing occurrence of infectious disease outbreaks and the rising prevalence of chronic ailments.
The biopharmaceutical industry was the largest contributor to the industry in 2023, with a 40.0% share, and it is likely to remain the largest during this decade.
The enhancing biopharmaceutical production infrastructure and R&D globally, to discover new molecule entities & vaccines against infectious ailments is driving the human vaccines category growth.
North America led the industry in 2023, with approximately 55% share, and it will further advance at a robust rate in the years to come.
The dominance of North America is because of the increasing incidence of rare, genetic, and chronic illnesses; the high technological improvement rate in the healthcare sector, and the rising number of R&D initiatives.
APAC is advancing at the fastest rate. This is because of the rising funding from both overseas and domestic biotech firms in this region and an enormous pool of patients with infectious and chronic ailments.
The red biotechnology industry is fragmented in nature, with the significant existence of large-scale companies.
These companies are involved in product launches, new product development, agreements, mergers, partnerships, and product approval to enhance their market presence.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by application
- 1.4.2. Market size breakdown, by product
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Application (2017-2030)
- 6.3. Market Revenue, by Product (2017-2030)
- 6.4. Market Revenue, by End User (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Application (2017-2030)
- 7.3. Market Revenue, by Product (2017-2030)
- 7.4. Market Revenue, by End User (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Application (2017-2030)
- 8.3. Market Revenue, by Product (2017-2030)
- 8.4. Market Revenue, by End User (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Application (2017-2030)
- 9.3. Market Revenue, by Product (2017-2030)
- 9.4. Market Revenue, by End User (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Application (2017-2030)
- 10.3. Market Revenue, by Product (2017-2030)
- 10.4. Market Revenue, by End User (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Application (2017-2030)
- 11.3. Market Revenue, by Product (2017-2030)
- 11.4. Market Revenue, by End User (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Application (2017-2030)
- 12.3. Market Revenue, by Product (2017-2030)
- 12.4. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Application (2017-2030)
- 13.3. Market Revenue, by Product (2017-2030)
- 13.4. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Application (2017-2030)
- 14.3. Market Revenue, by Product (2017-2030)
- 14.4. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Application (2017-2030)
- 15.3. Market Revenue, by Product (2017-2030)
- 15.4. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Application (2017-2030)
- 16.3. Market Revenue, by Product (2017-2030)
- 16.4. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Application (2017-2030)
- 17.3. Market Revenue, by Product (2017-2030)
- 17.4. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Application (2017-2030)
- 18.3. Market Revenue, by Product (2017-2030)
- 18.4. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Application (2017-2030)
- 19.3. Market Revenue, by Product (2017-2030)
- 19.4. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Application (2017-2030)
- 20.3. Market Revenue, by Product (2017-2030)
- 20.4. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Application (2017-2030)
- 21.3. Market Revenue, by Product (2017-2030)
- 21.4. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Application (2017-2030)
- 22.3. Market Revenue, by Product (2017-2030)
- 22.4. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Application (2017-2030)
- 23.3. Market Revenue, by Product (2017-2030)
- 23.4. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Application (2017-2030)
- 24.3. Market Revenue, by Product (2017-2030)
- 24.4. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Application (2017-2030)
- 25.3. Market Revenue, by Product (2017-2030)
- 25.4. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Application (2017-2030)
- 26.3. Market Revenue, by Product (2017-2030)
- 26.4. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Application (2017-2030)
- 27.3. Market Revenue, by Product (2017-2030)
- 27.4. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Application (2017-2030)
- 28.3. Market Revenue, by Product (2017-2030)
- 28.4. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Pfizer Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. F. Hoffmann-La Roche Ltd.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Merck KGaA
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. AstraZeneca PLC
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Takeda Pharmaceutical Company Limited
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Amgen Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Regeneron Pharmaceuticals Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Gilead Sciences Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Novartis AG
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
